Nootropics CAS 38821-49-7 Carbidopa 99% Purity Carbidopa Monohydrate Powder Pharmaceutical Carbidopa
Product Description
Product Details
| Product Name |
Carbidopa |
| CAS No. |
28860-95-9 |
| MF |
C10H14N2O4 |
| MW |
226.22916 |
| Appearance and shape |
White to off-white crystalline Powder |
Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth.
Carbidopa has a strong peripheral Dobart decarboxylase inhibitor. It is not easy to penetrate the blood-brain barrier. When it is used with levodopa, it only inhibits the activity of peripheral dobutase, reduces the generation of dopamine in the peripheral tissues, and alleviates its peripheral adverse reactions, thus increasing the levodopa entering the center, increasing the concentration of dopamine in the brain, and enhancing the efficacy of levodopa. Therefore, it is an important auxiliary drug of levodopa.
Application & Function
Carbidopa with strong outer peripheral dopa decarboxylase inhibitors. Easy through the blood-brain barrier, in combination with levodopa, suppress only the outer peripheral dopa decarboxylase activity, reducing the generation of dopamine in peripheral tissues, reduce adverse reactions outer periphery, thereby enabling an increase in levodopa into the hub, improve brain dopamine concentration, enhance the efficacy of levodopa, it is an important adjunct to levodopa.
Specification
Audited Supplier 
){kind=link}
){kind=link}